Market news

Management is forecasting a considerable slowdown in its revenue growth.

Novo Nordisk (NVO) concluded the recent trading session at $38.31, signifying a -1.03% move from its prior day's close.

Novo Nordisk (CPSE:NOVO B) entered an exclusive license with Hengrui Pharma for a once-weekly oral GLP-1/GIP dual agonist. Phase 3 CagriSema data delivered new weight management clinical results that add another late-stage asset to Novo Nordisk’s pipeline. The CHMP issued a positive opinion backing Sogroya for idiopathic short stature and supported FREHEMGO for hemophilia A patients. The Hengrui oral GLP-1/GIP deal and new trial wins tell only part of the Novo Nordisk story. We have also...

Novo Nordisk reports lower cardiovascular risk for semaglutide over tirzepatide and secures a $2.6 billion licensing deal.

Novo Nordisk Drops Big Ozempic Finding From 630,000-Patient Study

Novo Nordisk remains a compelling long-term investment despite a 70% share price decline amid GLP-1 competition. Click here to read this NVO stock update.

NVO and PFE offer different growth paths, with diversified portfolios, pipelines and near-term challenges shaping their outlooks.

Novo forges this deal as the company looks to extend the lead secured from its first-to-market advantage in the oral weight loss drug arena.

Lilly’s Foundayo 17.2 mg achieved a 1.5% greater weight loss and a 0.3% greater reduction in A1C than oral semaglutide 25 mg after 52 weeks.

Novo Nordisk licenses Hengrui’s obesity drug HRS-1596 in a deal up to $2.6B—see key terms, regions excluded, and what it means for investors.

Investing.com --Jiangsu Hengrui Pharmaceuticals (HK:1276) shares rose in Hong Kong on Tuesday after Novo Nordisk entered an agreement to license the Chinese drugmaker’s experimental obesity and diabetes treatment in a deal worth up to $2.6 billion.

Sept 29 () - Jiangsu Hengrui Pharmaceuticals, ‌China's largest drugmaker ‌by market value, ​said on Tuesday it will license global rights to ‌its ⁠weight-management drug HRS-1596 to Novo ⁠Nordisk A/S in a deal ​worth ​up ​to $2. Under ‌the agreement, Novo Nordisk gains exclusive rights to develop, manufacture and commercialise ‌the drug ​outside ​certain ​regions, with ‌the Danish drugmaker paying ​an ​upfront fee of $300 million.

Roche’s push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing an average of 15.5% of their body weight in a mid-stage trial. The results add another potentially important asset to Roche’s efforts to challenge obesity-market […]

Novo Nordisk (NYSE:NVO) finally has a CagriSema result it can put next to Eli Lilly’s (NYSE:LLY) tirzepatide and come out ahead. In the Phase 3 REIMAGINE 5 trial, adults with type 2 diabetes taking the 1 mg/ 1 mg dose of CagriSema lost an estimated 12.4% of their body weight after 60 weeks, compared with […]

Bagsværd, Denmark, 28 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme in

Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.

A stock that has lost more than 70% of its value from the peak tends to invite hard questions, and Novo Nordisk A/S (NYSE:NVO) is now facing them from its own investors. Late September 2026 brought renewed pressure on the company to explain what comes after its weight-loss drug franchise, as analysts project Eli Lilly’s […]

Novo Nordisk A/S (NYSE:NVO) has signed a drug-discovery and licensing agreement with Orbis Medicines worth up to $1.4 billion to develop oral therapies for cardiometabolic diseases that are traditionally treated with injections. The deal includes upfront and potential development and commercial milestone payments, tiered royalties on future sales, and a strategic investment by Novo in […]

Novo Nordisk A/S (NYSE:NVO) is defending its push to diversify beyond obesity as CEO Mike Doustdar signals that the company is willing to pursue deals to build growth outside its core weight-loss franchise. At its September 2026 Capital Markets Day, Novo said it aims to launch more than five multi-blockbuster medicines by 2030 and generate […]

Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) were once viewed as the two big winners of the GLP-1 boom. However, the market’s view of the two companies has changed sharply. Since mid-2024, Novo’s stock has fallen roughly 74%, while Lilly’s has gained about 35%. That difference is also reflected in their valuations, […]

The drugmaker badly needs more clinical wins.

Investing.com -- Viatris filed a lawsuit against Novo Nordisk in Delaware federal court, requesting a determination that its planned generic version of Wegovy would not violate the Danish company’s patent rights.

Novo Nordisk eyes M&A to counter patent cliff risks, and partners with Nanexa for long-acting injectables.

The latest installment in BioPharma Dive’s data visualization series features a closer look at Novo's stock performance and the recent run of fundraising success for AI drug discovery startups.

The collaboration covers up to five programs in obesity, diabetes and other cardiometabolic diseases.

Nanexa's shares more than doubled

The agreement gives Novo exclusive rights to Swedish startup Nanexa's drug-coating technology for up to 5 programs targeting obesity and diabetes

Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.

Nanexa AB (publ) ("Nanexa"), a Swedish drug delivery platform company developing long-acting injectable drugs based on its proprietary PharmaShell® technology platform, today announces that it has entered into a global exclusive license and collaboration agreement with Novo Nordisk ("Novo") for the use of the PharmaShell® technology platform for certain peptide-based drugs targeting obesity, type 2 diabetes and other cardiometabolic indications.

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.

Novo Nordisk (NYSE:NVO) has agreed to license drug-delivery technology from Swedish biotechnology company Nanexa in an agreement potentially worth up to €1. 165 billion.

Shares in Swedish microcap stock Nanexa more than doubled after the drug-delivery group revealed a licensing deal with European pharma giant Novo Nordisk.